Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab UseRobert L. Ferris, Maura L. Gillison, J. Guigay et al.|Clinical Cancer Research|2019Cited by 160
Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trialRobert I. Haddad, Robert L. Ferris, Fernando Concha‐Benavente et al.|Cancer|2019Cited by 98
Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomesRobert I. Haddad, Robert L. Ferris, George R. Blumenschein et al.|Annals of Oncology|2017Cited by 36